Kesler Norman & Wride LLC Sells 2,284 Shares of Aflac Incorporated (NYSE:AFL)

Kesler Norman & Wride LLC lowered its position in Aflac Incorporated (NYSE:AFL - Free Report) by 8.7% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 24,003 shares of the financial services provider's stock after selling 2,284 shares during the period. Kesler Norman & Wride LLC's holdings in Aflac were worth $2,483,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of AFL. Geode Capital Management LLC lifted its holdings in shares of Aflac by 2.4% during the fourth quarter. Geode Capital Management LLC now owns 12,465,433 shares of the financial services provider's stock worth $1,286,042,000 after buying an additional 288,482 shares during the last quarter. Tradewinds LLC. acquired a new position in Aflac during the 4th quarter valued at $476,000. National Bank of Canada FI boosted its holdings in Aflac by 0.9% in the 4th quarter. National Bank of Canada FI now owns 348,998 shares of the financial services provider's stock valued at $36,111,000 after purchasing an additional 3,195 shares during the period. Family Legacy Inc. grew its position in Aflac by 4.3% in the 4th quarter. Family Legacy Inc. now owns 2,607 shares of the financial services provider's stock worth $270,000 after purchasing an additional 107 shares during the last quarter. Finally, Summit Financial LLC increased its holdings in shares of Aflac by 0.6% during the 4th quarter. Summit Financial LLC now owns 19,269 shares of the financial services provider's stock worth $1,993,000 after purchasing an additional 123 shares during the period. 67.44% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

AFL has been the subject of a number of analyst reports. Piper Sandler raised their price objective on shares of Aflac from $118.00 to $124.00 and gave the stock an "overweight" rating in a report on Wednesday. Morgan Stanley increased their target price on Aflac from $98.00 to $105.00 and gave the stock an "equal weight" rating in a report on Friday, February 28th. Keefe, Bruyette & Woods decreased their price target on Aflac from $107.00 to $104.00 and set a "market perform" rating on the stock in a research note on Wednesday, February 12th. BMO Capital Markets initiated coverage on Aflac in a research note on Thursday, January 23rd. They set a "market perform" rating and a $111.00 price objective for the company. Finally, UBS Group upped their target price on shares of Aflac from $109.00 to $114.00 and gave the stock a "neutral" rating in a report on Wednesday. Two research analysts have rated the stock with a sell rating, eleven have given a hold rating and two have given a buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus price target of $104.29.

Insider Activity

In other Aflac news, Director Joseph L. Moskowitz sold 1,000 shares of the firm's stock in a transaction that occurred on Friday, March 7th. The shares were sold at an average price of $107.63, for a total transaction of $107,630.00. Following the completion of the transaction, the director now owns 25,393 shares in the company, valued at approximately $2,733,048.59. This trade represents a 3.79 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Charles D. Lake II sold 29,802 shares of the stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $107.29, for a total value of $3,197,456.58. Following the sale, the director now owns 49,962 shares of the company's stock, valued at approximately $5,360,422.98. The trade was a 37.36 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 0.90% of the company's stock.

Aflac Stock Down 8.8 %

Shares of Aflac stock traded down $9.81 during trading hours on Friday, reaching $101.94. 3,221,784 shares of the company's stock were exchanged, compared to its average volume of 2,138,854. Aflac Incorporated has a fifty-two week low of $79.31 and a fifty-two week high of $115.50. The stock has a market cap of $55.64 billion, a P/E ratio of 10.62, a P/E/G ratio of 3.24 and a beta of 0.81. The company has a current ratio of 0.10, a quick ratio of 0.08 and a debt-to-equity ratio of 0.29. The company has a 50 day moving average of $106.95 and a two-hundred day moving average of $107.70.

Aflac (NYSE:AFL - Get Free Report) last posted its quarterly earnings results on Wednesday, February 5th. The financial services provider reported $1.56 earnings per share for the quarter, missing analysts' consensus estimates of $1.63 by ($0.07). Aflac had a net margin of 28.76% and a return on equity of 16.20%. On average, sell-side analysts forecast that Aflac Incorporated will post 6.88 EPS for the current fiscal year.

Aflac Profile

Aflac Incorporated, through its subsidiaries, provides supplemental health and life insurance products. The company operates through Aflac Japan and Aflac U.S. segments. The Aflac Japan segment offers cancer, medical, nursing care, work leave, GIFT, and whole and term life insurance products, as well as WAYS and child endowment plans under saving type insurance products in Japan.